Form 8-K THRESHOLD PHARMACEUTICAL For: Jun 24
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) June 24, 2016
Threshold Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware (State or other jurisdiction of incorporation or organization) |
001-32979 File Number) |
94-3409596 (I.R.S. Employer Identification No.) |
170 Harbor Way, Suite 300 South San Francisco, California (Address of principal executive offices) |
94080 (Zip Code) |
Registrant’s telephone number, including area code: (650) 474-8200
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.07 Submission of Matters to a Vote of Security Holders
On June 24, 2016, the 2016 Annual Meeting of Stockholders (the “Annual Meeting”) of Threshold Pharmaceuticals, Inc. (the “Company”) was held at the Company’s corporate offices in South San Francisco, California. The Company’s stockholders voted on the following three proposals:
(1) Proposal to elect the three nominees named below as Class III directors to serve until the Company’s 2019 Annual Meeting of Stockholders and until their successors have been duly elected and qualified. Each of the two named nominees were so elected, with the votes thereon at the Annual Meeting as follows:
Final Voting Results
Nominee | For | Withheld | Broker Non- Vote | |||||||||
Bruce C. Cozadd | 23,555,165 | 870,513 | 28,653,540 | |||||||||
David R. Hoffmann | 23,787,297 | 638,381 | 28,653,540 | |||||||||
George G.C. Parker, Ph.D. | 23,872,857 | 552,821 | 28,653,540 |
The Company’s Class I directors, Jeffrey W. Bird and Harold E. Selick, will each continue to serve on the Company’s Board of Directors until the Company’s 2017 Annual Meeting of Stockholders and until his successor is elected and has qualified, or until his earlier death, resignation or removal. The Company’s Class II directors, Wilfred E. Jaeger and David R. Parkinson, will each continue to serve on the Company’s Board of Directors until the Company’s 2018 Annual Meeting of Stockholders and until his successor is elected and has qualified, or until his earlier death, resignation or removal.
(2) Proposal to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2016. This proposal was approved, with the votes thereon at the Annual Meeting as follows:
Final Voting Results
For | Against | Abstain | Broker Non-Vote | |||||||||||
52,438,272 | 499,343 | 141,603 | 0 |
(3) Proposal to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement for the Annual Meeting filed with the U.S. Securities and Exchange Commission on April 29, 2016. This proposal was approved, with the votes thereon at the Annual Meeting as follows:
Final Voting Results
For | Against | Abstain | Broker Non-Vote | |||||||||||
23,489,300 | 688,032 | 248,346 | 28,653,540 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Threshold Pharmaceuticals, Inc. | ||
Date: June 27, 2016 | By: | /s/ Joel A. Fernandes |
Name: Joel A. Fernandes | ||
Title: Vice President, Finance and Controller. |
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- F.N.B. Corporation Reports First Quarter 2024 Earnings
- Veritone Clinches 2024 NAB Product of the Year Award for a Fifth Time with Generative AI Solution
- 420 with CNW— Marijuana Biopharmaceutical Company Takes DEA to Court for Hindering its Cultivation Plans
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!